{
  "kind": "treatment",
  "slug": "eslicarbazepine-aptiom",
  "type": "mood-stabilizer",
  "name": "Eslicarbazepine (Aptiom)",
  "summary": "An anticonvulsant used primarily for partial-onset seizures, with off-label use as a mood stabilizer in bipolar disorder.",
  "description": "Eslicarbazepine acetate is a prodrug rapidly converted to eslicarbazepine, an active metabolite that blocks voltage-gated sodium channels, stabilizing hyperexcited neuronal membranes and inhibiting repetitive firing. It is FDA-approved for partial-onset seizures in epilepsy, but has been studied off-label for mood stabilization in bipolar disorder.",
  "category": "medications/mood-stabilizers",
  "tags": [
    "anticonvulsant",
    "mood stabilizer",
    "sodium channel blocker"
  ],
  "metadata": {
    "drug_classes": [
      "Anticonvulsant",
      "Mood Stabilizer"
    ],
    "therapeutic_categories": [
      "Epilepsy",
      "Bipolar Disorder"
    ],
    "mechanism_categories": [
      "Other"
    ],
    "administration_routes": [
      "Oral"
    ],
    "prescription_status": "Prescription Required",
    "controlled_substance": false,
    "generic_available": false,
    "brand_names": [
      "Aptiom"
    ],
    "dea_schedule": null,
    "fda_pregnancy_category": "C",
    "age_groups": [
      "Adult",
      "Pediatric (≥4 years)"
    ],
    "treatment_duration": [
      "Long-term"
    ],
    "specialty_areas": [
      "Neurology",
      "Psychiatry"
    ],
    "fda_approval_year": 2013
  },
  "clinical_metadata": {
    "primary_indications": [
      "Seizures"
    ],
    "off_label_uses": [
      "Bipolar Disorder (mood stabilization)"
    ],
    "contraindications": [
      "History of hypersensitivity to eslicarbazepine, oxcarbazepine, or carbamazepine"
    ],
    "monitoring_required": [
      "Sodium levels (risk of hyponatremia)",
      "Signs of hypersensitivity",
      "Seizure frequency"
    ],
    "efficacy_rating": {
      "seizures": 4,
      "bipolar_disorder_off_label": 2
    }
  },
  "search_metadata": {
    "searchable_terms": [
      "eslicarbazepine",
      "aptiom",
      "anticonvulsant",
      "sodium channel blocker"
    ],
    "synonyms": [
      "eslicarbazepine acetate"
    ],
    "common_misspellings": [
      "eslicarbazepin",
      "aptium"
    ]
  },
  "sections": [
    {
      "type": "indications",
      "items": [
        "Partial-Onset Seizures (monotherapy or adjunctive therapy)",
        "Bipolar Disorder (off-label)"
      ]
    },
    {
      "type": "mechanism",
      "text": "Blocks voltage-gated sodium channels, stabilizing hyperexcited neuronal membranes and inhibiting repetitive neuronal firing."
    },
    {
      "type": "dosing",
      "adult": {
        "partial_onset_seizures": "Start 400 mg once daily; increase weekly by 400–600 mg to maintenance 800–1600 mg once daily"
      },
      "pediatric": "10–30 mg/kg once daily; max 1800 mg/day",
      "geriatric": "Same as adult, but monitor sodium closely",
      "hepatic_impairment": "Mild/moderate: no adjustment; severe: not recommended",
      "renal_impairment": "Adjust if CrCl < 50 mL/min"
    },
    {
      "type": "dosage_forms",
      "items": [
        "Tablets: 200 mg, 400 mg, 600 mg, 800 mg"
      ]
    },
    {
      "type": "onset_duration",
      "text": "Seizure control improvement within days to weeks; steady-state reached in 4–5 days."
    },
    {
      "type": "adverse_effects",
      "common": [
        "dizziness",
        "somnolence",
        "headache",
        "nausea",
        "vomiting",
        "fatigue"
      ],
      "less_common": [
        "hyponatremia",
        "tremor",
        "blurred vision"
      ],
      "serious": [
        "Stevens-Johnson syndrome",
        "anaphylaxis",
        "suicidal thoughts/behaviors"
      ]
    },
    {
      "type": "warnings",
      "black_box": null,
      "other": [
        "May cause hyponatremia—monitor sodium",
        "Cross-sensitivity possible with carbamazepine or oxcarbazepine",
        "Monitor for suicidal ideation"
      ]
    },
    {
      "type": "interactions",
      "items": [
        {
          "with": "Carbamazepine",
          "risk": "Reduced eslicarbazepine levels",
          "action": "Monitor and adjust"
        },
        {
          "with": "Oral contraceptives",
          "risk": "Reduced efficacy",
          "action": "Use alternative contraception"
        },
        {
          "with": "Phenytoin",
          "risk": "Increased phenytoin levels",
          "action": "Monitor levels"
        }
      ]
    },
    {
      "type": "monitoring",
      "items": [
        "Sodium levels at baseline and periodically",
        "Signs of hypersensitivity",
        "Mood and suicidality"
      ]
    },
    {
      "type": "special_populations",
      "pregnancy": "Use only if benefits outweigh risks; registry available",
      "lactation": "Unknown excretion; use caution",
      "pediatrics": "Approved for ≥4 years for seizures",
      "geriatrics": "Increased risk of hyponatremia"
    },
    {
      "type": "tapering",
      "text": "Gradually taper over 1–2 weeks to avoid seizure recurrence."
    },
    {
      "type": "clinical_notes",
      "items": [
        "Structurally related to oxcarbazepine with potentially fewer side effects",
        "Once-daily dosing may improve adherence",
        "Off-label mood stabilizer use is less studied"
      ]
    },
    {
      "type": "references",
      "items": [
        {
          "label": "Aptiom Prescribing Information",
          "url": "https://www.accessdata.fda.gov/"
        },
        {
          "label": "Epilepsy Foundation Drug Database",
          "url": "https://www.epilepsy.com/"
        }
      ]
    }
  ],
  "seo": {
    "title": "Eslicarbazepine (Aptiom): Anticonvulsant and Mood Stabilizer",
    "description": "Eslicarbazepine (Aptiom) is an anticonvulsant used for partial-onset seizures and off-label as a mood stabilizer in bipolar disorder."
  }
}
